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ABSTRACT
Background: Abiraterone and enzalutamide are currently approved for mCRPC 
patients. Both drugs have distinct mechanisms of action and may have different 
toxicity profile. There are limited data comparing the side effects of abiraterone and 
enzalutamide. We performed a meta-analysis of randomized controlled trials (RCT) 
to better characterize the risk of adverse events associated with both drugs. 
Methods: We performed a literature search on MEDLINE for studies reporting 
abiraterone and enzalutamide side effects from January 1966 to July 31, 2015. 
Abstracts presented at ASCO meetings from 2004 to 2015 were selected manually. 
Phase III RCT were included in analysis. We assessed the risk of adverse events 
reported in RCT by performing two meta-analyses: abiraterone-prednisone vs. 
placebo-prednisone (2,283 pts) and enzalutamide vs. placebo (2,914 pts). Summary 
of incidence, relative-risks (RR), and 95% confidence intervals (CI) were calculated 
using random-effects or fixed-effects models based on the heterogeneity of included 
studies. 
Results: Overall, enzalutamide was not associated with all-grade (RR 1.06 - 95% 
CI 0.67-1.65) or grade ≥3 (RR 0.81 - 95% CI 0.28-2.33) cardiovascular events, but 
was associated with increased risk of all-grade fatigue (RR 1.29 - 95% CI 1.15-1.44). 
On the other hand, abiraterone was associated with increased risk of all-grade (RR 
1.28 - 95% CI 1.06-1.55) and grade ≥3 (RR 1.76 - 95% CI 1.12-2.75) cardiovascular 
events, but was not associated with all-grade (RR 0.85 - 95% CI 0.58-1.23) or grade 
≥3 (RR 1.07 - 95% CI 0.97-1.19) fatigue. 
Conclusions: In this meta-analysis, abiraterone was associated with an increased 
risk of cardiovascular events, while enzalutamide was associated with an increased 
risk of fatigue.
                                                                                Review
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INTRODUCTION
Prostate cancer is the second leading cause of cancer 
death among men [1]. Androgen deprivation therapy 
(ADT) is the standard treatment for advanced prostate 
cancer. Despite the excellent initial response to ADT, all 
patients will eventually develop resistance, thus leading 
to the phenotype of metastatic castration resistant prostate 
cancer (mCRPC). However, in the last few years, agents 
targeting the androgen receptor (AR) axis have shown to 
improve survival of patients with mCRPC [2] [3] [4] [5] 
[6]. Enzalutamide is a potent direct inhibitor of the AR, 
while abiraterone is a CYP17A1 inhibitor which in turn 
decreases androgen synthesis [7] [8]. Both are standard 
treatments for asymptomatic or mildly symptomatic 
docetaxel-naive mCRPC, and also for docetaxel treated 
patients. 
Overall, abiraterone and enzalutamide have a 
favorable toxicity profile. The most frequent adverse 
events are hot flashes and fatigue for enzalutamide and 
fluid retention, transaminase increases and hypokalaemia 
for abiraterone. This topic is of particular relevance in 
patients with mCRPC, who may have a high number of 
comorbidities.
In this report, using a meta-analysis design, 
we sought to investigate the differential incidence of 
cardiovascular events and fatigue as side effects of 
abiraterone and enzalutamide in mCRPC patients. The 
two most important clinical toxicities reported for these 
drugs are cardiotoxicity for abiraterone and fatigue for 
enzalutamide. Other exploratory toxicities were not 
included to avoid the risk of positive findings due to 
multiple comparisons. 
RESULTS
Literature search and trials
Figure 1 describes the flow chart for study selection 
and Table 1 summarizes the included studies.
Abiraterone toxicities
Abiratrone was used in association with prednisone 
and compared to placebo plus prednisone. Abiraterone 
plus prednisone was associated with a statistically 
significant 76% increase in the risk of high-grade cardiac 
disorder adverse events (RR 1.76; IC95% 1.12-2.75; p = 
0.01) and in a 28% percent increase in all-grade cardiac 
disorder adverse event (RR 1.28; IC95% 1.06-1.55; p = 
0.01). On the other hand, abiraterone plus prednisone was 
neither associated with an increased risk of all-grade nor 
high-grade fatigue. These results are presented in figure 
2-3. 
Enzalutamide toxicities
Enzalutamide was not associated with an increase in 
the risk of all-grade or high-grade cardiac disorder adverse 
Figure 1: Selection process for randomized controlled trials included in the meta-analysis.
Oncotarget84574www.impactjournals.com/oncotarget
event. However, it was associated with an increased risk 
of all-grade fatigue by 29% (RR 1.29; IC95% 1.16-1.44; 
p < 0.01), but not the risk of high-grade fatigue (RR 0.89; 
IC95% 0.62-1.29; p = 0.55). Figure 2-3 summarizes these 
results. 
DISCUSSION
To the best of our knowledge, this is the first 
study to separately evaluate the risk of adverse events 
reported in RCT of Abiraterone and Enzalutamide. A 
network meta-analysis was not performed due to the 
lack of a common arm between trials; Abiraterone plus 
prednisone was compared to placebo plus prednisone 
while enzalutamide was compared to placebo alone. 
The presence of prednisone in one of the placebo arms 
represents a systematic difference between comparators 
that would probably interfere with the probability of 
adverse events in these arms making them impossible 
to combine. Therefore, we carried out two separate 
pairwise meta-analyses which demonstrate that patients 
receiving enzalutamide have a higher risk of all-grade 
fatigue, but not of all-grade or high-grade cardiovascular 
events, whereas abiraterone is associated with all-grade 
and high-grade cardiovascular toxicity, but not with all-
grade or high-grade fatigue. With regard to abiraterone 
cardiovascular side-effects, the incidence and relative risk 
of cardiovascular events of the new hormonal agents for 
Table 1: Characteristic of the included studies















(phase III) 2011 1185
Abiraterone + Prednisone 
(791) 69 (42-95) 5.6 14.8 12.8 5
Prednisone (394) 69 (39-90) 3.6 10.9
COU-AA-302 
(phase III) 2013 1082
Abiraterone + Prednisone 
(542) 71 (44-95) 16.5 nr 22.2 5
Prednisone (540) 70 (44-90) 8.3 27.2
AFFIRM  
(phase III) 2012 1199
Enzalutamide (800) 69 (41-92) 8.3 18.4 14.4 5Placebo (399) 69 (49-89) 3.0 13.6
PREVAIL 
(phase III) 2014 1717
Enzalutamide (872) 72 (43-93) 11.2 32.4
22.0 5Placebo (845) 71 (42-93) 2.8 30.2
Figure 2: Relative risk for (A) Any grade and (B) ≥ 3 fatigue in patients treated with Abiraterone or Enzalutamide
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mCRPC, including abiraterone, have been investigated in 
a recent network meta-analysis [9]. This study evaluated 
the toxicities reported in RCT (n = 6) of these drugs and 
reported that their use is associated with an increased 
risk of all-grade cardiotoxicity (RR=1.32; 95% CI=1.08-
1.60; p = 0.006) but not with an increased risk of grade 
≥3 cardiac events, compared with a placebo. However, 
the analyzed agents included the novel CYP-17 inhibitor 
TAK 700 which, due to the negative results in terms 
of OS achieved, is not approved for the treatment of 
prostate cancer [10] [11] and, notably, enzalutamide. As 
mentioned above, the control arms of Enzalutamide RCT 
differed from those of abiraterone and TAK 700 as it did 
not include prednisone, which represents a considerable 
bias for a network meta-analysis as the one performed. At 
any rate, a sub-analysis of enzalutamide toxicity only from 
this study observed no significant increase of all-grade 
or high-grade adverse cardiac events, as proven also in 
our study [9]. Furthermore, a contemporary metanalysis 
analyzed the toxicity data from 4 RCT of the CYP-17 
inhibitors Abiraterone and TAK 700 in order to determine 
the incidence and relative risks of side-effects of special 
interest in patients with mCRPC treated with these agents 
[12]. Administration of CYP-17 inhibitors was found to 
be associated with a significant increased risk of all-grade 
(RR=1.47; 95% CI=1.27–1.7; p < 0.00001) and grade ≥3 
(RR=1.55; 95% CI=1.18–2.05; p = 0.002) cardiovascular 
disorders. Particularly, in the subset analysis of abiraterone 
versus TAK 700, a significantly lesser risk of grade ≥3 
cardiac adverse events was shown in favor of TAK 700. 
Taken together, these data seem to support our results. 
In contrast, in a retrospective study of mCRPC patients 
with preexisting cardiovascular risk factors treated with 
abiraterone, no grade ≥3 cardiac toxicity was described. 
The authors concluded that abiraterone appears a safe 
option even for patients with cardiac comorbidities [13]. 
However, the multiple drawbacks of this study, including 
the small population (n = 51), the retrospective analysis, 
and the fact that all patients cardiac comorbidities were 
controlled with appropriate therapy prior to starting 
abiraterone, should be taken into account. Conversely, 
as the stringent inclusion criteria of RCT do not allow 
recruitment of patients with inadequate organ function 
or chronic or concomitant diseases, we deem that our 
analysis might underestimate the risk of cardiovascular 
toxicity for the real-world clinical population treated with 
abiraterone. Furthermore, it should be considered that 
the vast majority of these patients has been previously 
exposed to long-term androgen deprivation therapy (ADT) 
which in several studies was associated with an increased 
risk of cardiovascular disease [14] [15].
Therefore, we suggest careful consideration of 
the risks and possible benefits of abiraterone therapy 
for mCRPC patients with cardiovascular comorbidities 
(i.e. cardiac ischemia, congestive heart failure, recent 
myocardial infarction, arrhythmias) or a history of cardiac 
disease. Lastly, it may be reasonable to recommend 
performing a detailed cardiovascular assessment prior 
Figure 3: Relative risk for (A) Any grade and (B) ≥ 3 cardiac event in patients treated with Abiraterone or Enzalutamide
Oncotarget84576www.impactjournals.com/oncotarget
to starting Abiraterone and periodical monitoring during 
treatment.
As much as abiraterone-related cardiotoxicity can 
represent a life-threatening side effect, enzalutamide-
related fatigue should not be disregarded. Even if this 
analysis does not show a higher risk of grade ≥3 fatigue 
for patients treated with Enzalutamide, our results 
demonstrate an association with increased risk of all-
grade fatigue. It is commonly acknowledged that fatigue 
may have a major impact on patients’ quality of life 
[16], self-care abilities [17], and psychological status. 
That holds particularly true for CRPC patients who are 
typically elderly, with comorbidities and at an advanced 
stage of disease. Additionally, most men candidate to 
enzalutamide have been previously treated with long-
term ADT. Fatigue is a common and frequently under-
recognized adverse event of ADT [18] and has been 
consistently described in the literature as enhancing in 
terms of severity, interference, and duration over the 
course of ADT [19] [20]. Furthermore, it has been recently 
proven that a greater number of baseline comorbidities and 
a higher baseline Gleason score correlate with a worsened 
fatigue trajectory in men receiving ADT [19]. Therefore, 
we deem that these risk factors should be part of an 
accurate screening aimed to select those patients who are 
less likely to be excessively burdened by this debilitating 
symptom receiving Enzalutamide. Lastly, fatigue 
should be adequately monitored by means of validated 
questionnaires (Cancer Fatigue Scale) throughout 
treatment. 
As both abiraterone and enzalutamide demonstrated 
similar efficacy prior to and after chemotherapy in 
mCRPC patients [3] [4], the treatment decision-making 
should be aided by a careful analysis of patient competing 
risks of death, chiefly a history of cardiovascular disease 
or cardiac comorbidities, and patient baseline conditions, 
particularly fatigue. Besides, a thorough discussion with 
the patient surrounding the possible risks and benefits 
of each therapy is warranted and appropriate monitoring 
during treatment is required. 
We are aware that several limitations apply to this 
study. First, our analysis hinges on solely 4 RCT and not 
on individual patient data; second, the analyzed RCT 
adopted different versions of the Common Terminology 
Criteria for Adverse Events (CTCAE); third, our findings 
are based on RCT data which might not reflect the real-
world setting due to the RCT strict inclusion/exclusion 
criteria; fourth, other exploratory toxicities were not 
included.
Despite these drawbacks, our analysis shows an 
increased risk of all-grade and grade ≥3 cardiovascular 
events for abiraterone and a higher risk of all-grade 
fatigue for enzalutamide. These findings provide a better 
understanding of the divergent side effect profile of these 
drugs and may help selecting the more appropriate therapy 
for each patient on the basis of his baseline comorbidities, 
cardiovascular history, and conditions. 
MATERIALS AND METHODS
Literature search and study selection
MEDLINE was searched from January 1966 to 31 
May, 2016 and ASCO meetings abstracts were manually 
selected from 2004 to 2016. The MeSH terms used for 
searching PubMed and the Cochrane Library were 
‘abiraterone’ or ‘enzalutamide’. The ASCO University 
abstracts were searched using the name of the drugs and 
the terms ‘phase II’ or ‘phase III’. Search was restricted 
to randomized phase II or III clinical trials reported in 
English. Title and abstracts of all the original reports 
identified were reviewed by two independent authors 
(R.B.M. and F.A.S) for inclusion in this meta-analysis. 
Cases of disagreement were adjudicated by consensus 
among reviewers. The full texts of all potentially relevant 
studies were downloaded and reviwed by two independent 
authors (R.B.M. and F.A.S) for inclusion in this meta-
analysis. Cases of disagreement were adjudicated by 
consensus among reviewers. 
The inclusion criteria for this meta-analysis were: 
[1] prospective randomized phase II or III trials involving 
patients with mCRPC and [2] random assignment of 
patients to study drug (biraterone or enzalutamide) or 
control. Study quality was assessed by using the seven-
point Jadad ranking system that included randomization, 
double-blinding, and withdrawals, a practice in agreement 
with other meta-analyses done in this context [21].
Data extraction
Identified abstracts were then collected and coded 
by two investigators (R.B.M. and F.A.S) according to 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement [22] and any 
discrepancies between reviewers were resolved by 
consensus. For each study, the following information was 
extracted: first author’s name, year of publication, trial 
phase, number of enrolled subjects, number of patients 
included in the safety analysis, treatment arms, number 
of patients in abiraterone or enzalutamide treatment and 
control groups, underlying malignancy, median age, 
median progression-free survival, overall survival, adverse 
events of interest.
Statistical analysis
The outcomes included in this meta-analysis of 
treatment toxicities were all grade and high-grade any 
cardiac event and fatigue. Cardiac toxicity was defined by 
Oncotarget84577www.impactjournals.com/oncotarget
the following events: ischaemic heart disease, myocardial 
infarction, supraventricular tachyarrhythmias, ventricular 
tachyarrhythmias, cardiac failure, and possible arrhythmia-
related investigations, signs, and symptoms. Treatment 
effects were pooled as relative risks (RR). All comparisons 
were based on two-tailed tests and p-values lower than 
0.05 were considered significant.
Heterogeneity was accessed using Cochrane Q test 
and I2. Heterogeneity was considered significant whenever 
the Cochrane Q test yields a p-value under 0.10 or the I2 
resulted higher than 50%. If heterogeneity was deemed not 
to be significant, the generic inverse variance fixed effect 
(Mantel Haenszel) was used; while the use of the random-
effect method (DerSimonian) was reserved for cases of 
significant heterogeneity. Statistical analysis were carried 
out using the version 5.3 of the software RevMan.
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